Loading…

Rare frameshift mutation Cys475Tyrfs()11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia

Saved in:

Bibliographic Details
Published in:	Annals of laboratory medicine 2012-11, Vol.32 (6), p.452
Main Authors:	Park, Sang Hyuk, Chi, Hyun-Sook, Kwon, Mi-Ryang, Cho, Young-Uk, Jang, Seongsoo, Park, Chan-Jeoung
Format:	Article
Language:	English
Subjects:	Adult Antineoplastic Agents - therapeutic use Asian Continental Ancestry Group - genetics Base Sequence Benzamides - therapeutic use Drug Resistance, Neoplasm Female Frameshift Mutation Fusion Proteins, bcr-abl - genetics Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Male Piperazines - therapeutic use Pyrimidines - therapeutic use Republic of Korea Sequence Analysis, DNA Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!